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Background: The safety and efﬁcacy of the Absorb (Abbott) bioresorbable
vascular scaffold (BVS) has been documented in lower-risk patient and lesion subsets
with “real-world” outcome data being scarce. Here we report the experience gathered
with BVS primarily in daily practice at a high-volume Dutch center.
Methods: Between July 2009 - April 2014, a total of 169 patients (194 lesions)
were treated with BVS, of which the ﬁrst 36 patients were treated within the scope
of the ABSORB studies. Clinical presentation of pts. (75% male, mean age 58 yrs,
16% diabetes) was ACS in 47%. Multi-vessel disease was present in 39%. Lesion
complexity was B2/C in 59% and mean lesion length 18.2 mm. Pre-dilatation was
performed in 96% and post-dilatation in 54%. The mean scaffold length was 29
mm with 34% of cases using 2 scaffolds and 25% of cases using overlapping or
adjacent scaffolds. OCT or IVUS was used in 42%. Registry data was collected
prospectively in-hospital, at 1 and 6 months and then yearly up to 4 years. Mean
follow-up time was 298 days (range 0-1534 days) with 46% of patients having at
least 1 year of follow-up.
Results: Procedural success was 99.4% (failure to achieve stent-expansion in 1 pt.)
and device success 98.8% (failure to deliver BVS in 2 pts.). Over the entire follow-up
period, death occurred in 2.4% (2 cardiac and 2 non-cardiac), myocardial infarction
(MI) in 3.0% (total of 5 cases, 1 of peri-procedural), target lesion revascularization in
3.6 %, target vessel revascularization (TVR) in 4.2%, non-target vessel revasculari-
zation 0.6%. Deﬁnite stent thrombosis (ST) occurred in 3 pts. (1.8%) and probable ST
in 1 pt. (0.6%); all ST were early within 48 hours except one case of deﬁnite ST which
occurred at 7 months. Overall MACE (death, MI, TVR) during follow-up occurred in
8.3% of patients (n¼14).
Conclusions: This registry including patients with ACS and complex lesion charac-
teristics documents a good efﬁcacy and reasonable safety proﬁle of the BVS. Stent
thrombosis, in particular early after BVS implantation, is not infrequent and has to be
closely monitored. Randomized data is needed to deﬁne the role of BVS in daily
practice including complex patient and lesion subsets.
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Background: Bioresorbable vascular scaffolds (BVS, Abbott Vascular, Santa Clara,
California, USA) are new options for treatment of coronary stenoses. Due to a large
crossing proﬁle, the implantation procedure is more complex than for current metal
stents. Thus, a learning curve might be present. We analyzed whether there is a
relationship between the outcome of coronary PCI with BVS and speciﬁc operator
experience with this treatment modality.
Methods: 200 consecutive patients included in a multi-center all-comers registry of
coronary revascularization procedures with BVS were divided into the ﬁrst 100
(group A) vs. the second 100 individuals (group B). We compared procedural
parameters and complication rates, as well as in-hospital outcome and mid-term
follow-up results.
Results: Baseline characteristics in both groups were not signiﬁcantly different. The
number of implanted BVS was 131 (1.2 per patient) in group A versus 149 (1.4 per
patient) in group B (p¼n.s.). No differences were documented between group A and
B for median procedure time (48 vs. 51 min; p¼n.s.), mean contrast volume (195.0
 100.0 mL vs. 183.2  80.4 mL; p¼n.s.), mean ﬂuoroscopy time (13.7  8.7min
vs. 13.9  8.1min; p¼n.s.), or number of predilatations performed (1.4:  0.8 vs.
1.4  1.4; p¼n.s.). However, post dilatation (23.8% vs. 50.5%, p< 0.01) and
intravascular imaging (9% vs. 19%, p< 0.05) were used signiﬁcantly more
frequently in group B. There was no difference in the rates of severe procedure
related complications (group A: 2%; group B: 3%, p ¼n.s.), in-hospital MACE (2%
vs. 3%, p¼n.s.), or median length of hospital stay (4 days in both groups). During
follow-up (median 210 vs. 192 days, p ¼ n.s.) total rates of MACE, TVF and TVR
where signiﬁcantly higher in group A (MACE: 12% vs. 3%, p< 0.05; TVF: 9% vs.
2%, p< 0.05; TVR: 9% vs. 2%, p< 0.05). Additionally, TLR rate tended to be
higher in group A (6% vs. 2%; p¼n.s.).
Conclusions: The ﬁndings of this registry suggest that in an all-comers population
BVS implantation beneﬁts from operator experience with the device and from routine
use of post-dilatation. The use of intravascular imaging to guide implantation might be
favorable.B182 JACC Vol 64/11/Suppl B j September 13–1TCT-624
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Background: Although bioresorbable scaffolds (BRS) may have important beneﬁts,
their deployment requires more aggressive lesion preparation compared to the best
metallic DES due to different radial force and crossing proﬁle. In addition, the beneﬁts
of post dilatation (PD) have not been systematically studied, with reports of fracture if
the BRS expansion limits are exceeded by excessive PD. We sought to determine the
impact of PD on clinical outcomes in a large cohort of patients treated with the Absorb
only.
Methods: We evaluated all consecutive patients enrolled in the multicenter, single
arm ABSORB EXTEND Study through June 2013. The study allowed treatment of up
to 2 coronaries (diameter 2.0 to 3.8mm) and the use of overlapping (lesion length 
28mm). Patients with severe lesion calciﬁcation/tortuosity were excluded. Aggressive
lesion pre dilatation (balloon to artery ratio of 0.9-1.0) was mandatory and PD was left
to the operator’s discretion (if performed, non-compliant balloons up to 0.5mm larger
than the Absorb had to be used). Patients were grouped according to whether PD was
performed or not, and the one-year incidence of TLF and scaffold thrombosis were
compared.
Results: 768 patients were enrolled in the study and PD was performed in 526
(68.4%). There were no signiﬁcant differences between the PD group and no-PD
group in baseline characteristics, moderate calciﬁcation (13.7% vs.12.7%, p¼0.7) and
incidence of B2/C lesions (43.9% vs. 41.8%), as well as lesion length (12.3mm vs.
12.1mm, p¼0.6) and RVD (2.6mm for both groups, p¼0.2). Residual in-scaffold
stenosis (15.4  6.5% with PD, 14.9  6.1 without PD, p¼0.3) and the need for
bailout scaffold/stent (4.2% with PD, 4.5% without PD, p¼0.8) were also comparable.
At 1 year, there was no difference in TLF (5.4% in the PD vs. 2.6% in the non-PD
group, p¼0.13); all individual components of TLR, death, and MI were also similar.
There were no signiﬁcant differences in MACE and def/probable stent thrombosis
between the two groups.
Conclusions: These results reﬂect very similar ﬁnal angiographic and clinical results
achieved with or without post-dilatation in the treatment of low to moderately com-
plex lesions.
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Background: In order to assess the long term safety, clinical performance and the
bioabsorption process of the paclitaxel-eluting absorbable magnesium Scaffold
(DREAMS) 3-year clinical data and multi-modality imaging outcomes are reported.
Methods: Forty-six subjects were enrolled in the ﬁrst-in-man BIOSOLVE-I study in
two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months; angio-
graphic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12-month. A
subgroup of patients underwent OCT and vasomotion testing. The primary endpoint is
Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12-month for cohort 2. For
some patients also 18-month and 24-month imaging data are available.
Results: TLF rate at 36-month was 6.8% including 2 TLRs and 1 peri-procedural MI
occurring at the 12-month follow-up angiography; no events emerged from 12- to 36-
month. No cardiac death or scaffold thrombosis was observed. Vasoconstriction after
acetylcholine at 6-month (delta¼-10.04%; p¼0.0008 versus baseline) followed by
vasodilatation after nitroglycerine (delta¼8.69%; p< 0.0001 versus baseline) dem-
onstrates the uncaging aspect of the absorption process with no further change at the
12-month follow-up. Six-month virtual histology (VH) data showed a signiﬁcant
decrease in the dense calcium by 39.5% (p¼0.0015) remaining stable from 6- to 12-
month follow-up. This decrease is interpreted as a surrogate assessment for the bio-
absorption process of the scaffold material. Echogenicity data using the decrease in
intensity of the ultrasound signal to quantify the change in strut structure demonstrate
a continuous decrease in % hyperechogenicity over the follow-up period, with the
most pronounced changes within the ﬁrst 6 months (22 to 16% p< 0.001).7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: DREAMS shows excellent safety and efﬁcacy data with no death and
no scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality im-
aging documented the absorption process and the uncaging aspect of this device
already at 6 months.
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Background: Bioresorbable stents have not been evaluated in a wide range of clinical
settings including ACS, STEMI, in-stent restenosis, SVG, and CTO. As of April 1st
2013, ABSORB BVS (BVS) became our default drug eluting device for patients at
our institution. The aim of this study is to evaluate the safety and efﬁcacy of this new
technology in a real-world setting.
Methods: Detailed patient characteristics and peri-procedural data are collected for
both patients receiving and not receiving a BVS and systematically entered in a
registry. In-hospital outcomes include MACE and bleeding complications and are
independently assessed by dedicated personnel.
Results: We will report on our ﬁrst year experience with BVS. Results are compared
to those in a group of patients treated concomitantly with other stent types. As of
March 31st 2013, 504 BVS have been implanted in 339 patients. Unadjusted MACE
(death, MI, Urgent PCI) rates were 2.0%, 2.4%, and 3.9% in patients treated with
BVS, DES and BMS, respectively.
Conclusions: Conclusions will be supported by the presented data and will reﬂect our
main ﬁndings. Preliminary results suggest comparable clinical outcomes with BVS
and DES in patients without contra-indication to drug-eluting devices.
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Background: The strut thickness and deliverability of BVS may increase procedural
time, contrast volume and ﬂuoroscopy time, especially in complex lesions.
Methods: In this study, 205 consecutive patients treated with either BVS (n¼99)
or drug eluting stent (DES) (n¼106) between May 2010 and May 2014 were
enrolled.
Results: The number of complex lesions (ACC/AHA lesion classiﬁcation type B2
and C) between BVS and DES group (84.7% vs. 90.6%, p¼0.01) was similar.
Pre and post-balloon dilatation were performed more frequently in the BVS
group compared to the DES group (97.1% vs. 79.4%, p< 0.01; 99.2% vs.
79.4%, p< 0.01, respectively). Maximum post dilatation balloon size was larger
and maximum inﬂation pressure was higher in the BVS compared to the DES
group (3.20.4 mm vs. 3.00.1 mm, p¼0.01; 21.15.1 atm vs. 19.25.0 atm,
p< 0.01, respectively), despite similar quantitative coronary angiogram (QCA)
results. Procedure time, amount of contrast and ﬂuoroscopy time in BVS group
were increased signiﬁcantly compared to those in the DES group (Table). In
multivariable analysis, after adjustment for SYNTAX score, chronic total oc-
clusion and lesion length by QCA, BVS use was identiﬁed as an independent
predictor of long procedure time (> 120 min.) (odds ratio: 4.9, 95% conﬁdence
interval: 2.67-9.36, p< 0.001).BVS
(patient n ¼ 99)
DES
(patient n¼ 106) P-value
Total procedure time, min 114.7  39.2 90.4  38.2 < 0.01
Total amount of contrast, ml 268.3  104.2 229.2  122.2 0.02
Total ﬂuoroscopy time, min 42.4  17.9 34.5  19.7 < 0.01Conclusions: Treating complex lesions with BVS requires longer procedure/
ﬂuoroscopy times and larger volumes of contrast as compared to DES implan-
tation to achieve similar procedural success rates and results. Improvements in
scaffold design may reduce the need for meticulous lesion predilatation with
dedicated devices and increase the spectrum of lesions amenable to treatment
with BVS.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteTCT-628
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Background: Everolimus-eluting bioresorbable vascular scaffolds (BVS) are
increasingly used in patients with complex coronary anatomies. However, data on
BVS in such indications are scarce. We thus sought to evaluate the safety and efﬁcacy
of ABSORB BVS in patients with complex coronary lesions.
Methods: Consecutive patients (n¼150) undergoing BVS implantation at a tertiary
care center entered a prospective registry. All patients underwent a detailed assessment
of clinical and procedural data. Clinical follow-up was performed 75 months
following the index procedure and was completed in all patients. Major adverse
cardiac events (MACE) included the occurrence of death, myocardial reinfarction,
stent thrombosis and target lesion revascularization. Complex coronary artery disease
was deﬁned as type B2 or C lesions. Device success was deﬁned as attainment of <
30% ﬁnal residual stenosis. Procedural success was deﬁned as device success without
periprocedural complications. Clinical success was deﬁned as procedural success and
absence of MACE within follow-up.
Results: Complex coronary lesions were present in 45.3% (n¼68) of patients.
Baseline characteristics such as age, gender or left ventricular ejection fraction did
not differ signiﬁcantly between patients with type B2/C lesions versus those with
type A/B1 lesions (all p>0.05). The number and length of BVS were higher in
patients with complex lesions (1.40.6 vs. 1.10.3, p< 0.001 / 3213 vs.
196mm, p< 0.001). Device success rate was high in both groups (97.1 vs.
97.6%, p¼1.00). At a relatively low rate of periprocedural complications (edge
dissection n¼7, side branch occlusion n¼2) procedural success did not differ
signiﬁcantly in patients with complex lesions in comparison to patients with non-
complex lesions (91.2 vs. 95.1%, p¼0.51). The majority of patients remained free
of angina within follow-up (85.3 vs. 92.7%, p¼0.19). MACE occurred in 1.5%
(n¼1) of patients with type B2/C lesions versus 7.3% (n¼6) with type A/B1 le-
sions (p¼0.13). Finally, clinical success was comparable in both groups (89.7 vs.
87.9%, p¼0.80).
Conclusions: BVS in complex coronary lesions appear to be promising in terms of
safety and efﬁcacy.
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Background: One of the hypothesized long-term clinical beneﬁts of Absorb BVS is
plaque regression (reduction in plaque volume) and stabilization (reduction in necrotic
and lipid composition). This study evaluates the effect of Absorb BVS on plaque size
and composition in a familial hypercholesterolemic (FH) swine model. We present
here the IVUS results at 1-year follow-up.
Methods: Ten-month-old female FH swine were fed an atherogenic diet for 21 weeks.
One week into the feeding, coronary arteries were balloon injured. Twenty weeks post
injury, intervened segments were imaged by IVUS for lesion progression and
randomly implanted with either Absorb BVS or metallic drug-eluting stents (DES,
XIENCE V) at a 2:1 ratio. All animals were imaged by angiography, IVUS and
OCT post implant and at an interim 1-year follow up.
Results: Plaque area (PA), %PA (as percentage of EEL area) and plaque tissue
composition were statistically similar for both device groups at pre and post implant
(baseline) demonstrating a good randomization of the study. At 1-year follow-up, the
implanted vessel (Absorb ¼ 23, DES ¼ 11) sizes remained unchanged. Change in the
mean PA from baseline to 1 year was -0.222.61mm2 for BVS and 1.151.36mm2
for DES (p ¼ 0.05). Changes of mean %PA were 112% and 76% for BVS and
DES (p¼0.07), respectively. There was a signiﬁcant decrease of %PA at MLD
(minimal lumen diameter) in BVS (-812%) compared to metallic DES (48%)
(p¼0.01). Plaque tissue characterization (iMAP-IVUS, Boston Scientiﬁc) revealed
that percentage changes of each plaque component were the same between the two
device groups with a decrease of ﬁbrotic and increase of lipid and necrotic
components.
Conclusions: At 1 year, plaque size trended towards reduction in Absorb but not
in metallic DES implanted vessels. Plaque tissue characterization suggests that
plaque stabilization has not occurred at 1 year; however, plaque stabilization is
hypothesized to be related to tissue replacement of polymeric struts and as such
expected during later stages of resorption. This hypothesis will be examined with
repeat in vivo imaging follow-up and histological evaluation in these animals at 2,
3, and 4 years.nts - Drug-eluting: Bioresorbable Scaffolds B183
